Galderma Group AG

Stocks

Market Closed - Swiss Exchange Other stock markets 11:31:24 2026-07-15 am EDT			5-day change	1st Jan Change
166.60 ^CHF	-1.27%		-4.83%	+2.78%

Jul. 09	RBC Expects Slowdown in Galderma's Q2 Sales Growth; Price Target, Estimates Revised	MT
Jul. 08	Swiss Market Index Slips Back into Red; Barry Callebaut Shares Down	MT

Published on 04/23/2026 at 11:35 am EDT - Modified on 04/23/2026 at 03:20 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day, and thank you for standing by. Welcome to Galderma's Q1 2026 Trading Update Conference Call. [indiscernible] Please be advised that today's

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Jul. 09	RBC Expects Slowdown in Galderma's Q2 Sales Growth; Price Target, Estimates Revised	MT
Jul. 08	Swiss Market Index Slips Back into Red; Barry Callebaut Shares Down	MT
Jul. 08	CH Closer	MT
Jul. 08	CH Closer	MT
Jul. 03	Galderma Group Forecasts Revised as BofA Notes US FDA Response to Relfydess Application	MT
Jul. 01	Health Care Up on AI Rotation - Health Care Roundup	DJ
Jul. 01	Swiss Market Index Blinks Red; Galderma Falls	MT
Jul. 01	Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S. -- Update	DJ
Jul. 01	European Midday Briefing : Shares Lower After Posting Strong Quarter	DJ
Jul. 01	Galderma Shares Fall After Bid to Launch Botox Rival in U.S. Hits FDA Setback	DJ
Jul. 01	Galderma Application for Product to Rival Botox Turned Down Again by FDA	DJ
Jul. 01	US FDA Responds to Galderma's Bologics License Application for Liquid Neuromodulator	MT
Jul. 01	Galderma Provides Progress Updates Regarding Regulatory Review of its Pending Biologics License Application for RelabotulinumtoxinA with U.S. Food and Drug Administration	CI
Jul. 01	Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States	CI
Jun. 26	Swiss stocks - Factors to watch on June 26	RE